Wall Street Zen Downgrades REGENXBIO (NASDAQ:RGNX) to Sell

REGENXBIO (NASDAQ:RGNX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other equities research analysts also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of REGENXBIO in a research report on Thursday. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday. Royal Bank Of Canada increased their price objective on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus upped their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

REGENXBIO Stock Down 3.8%

RGNX opened at $11.16 on Friday. REGENXBIO has a 52-week low of $5.03 and a 52-week high of $16.19. The company has a 50 day moving average of $13.72 and a two-hundred day moving average of $11.35. The company has a market cap of $564.92 million, a P/E ratio of -3.22 and a beta of 1.05.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The business had revenue of $29.73 million for the quarter, compared to analyst estimates of $24.41 million. Research analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current year.

Institutional Trading of REGENXBIO

A number of hedge funds have recently made changes to their positions in RGNX. Voss Capital LP boosted its stake in REGENXBIO by 47.4% during the 2nd quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock valued at $4,721,000 after acquiring an additional 185,000 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of REGENXBIO by 23.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 705,403 shares of the biotechnology company’s stock worth $6,807,000 after purchasing an additional 132,942 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of REGENXBIO by 2,049.0% in the 2nd quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock valued at $1,800,000 after purchasing an additional 209,084 shares in the last quarter. 22NW LP lifted its position in shares of REGENXBIO by 38.1% during the second quarter. 22NW LP now owns 923,679 shares of the biotechnology company’s stock worth $7,583,000 after purchasing an additional 255,000 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in REGENXBIO in the second quarter worth about $1,453,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.